DuPont de Nemours Q3 2026 earnings

DD · 2026-11-03 08:05 BMO ET · 8-K on SEC

Strong execution with mid-single digit organic growth, margin expansion, and robust free cash flow conversion exceeding guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.87B+4%+3%Ex. 99.1, income statement
EPS (GAAP)$1.24+77%-9%Ex. 99.1, income statement
EPS (adjusted)$2.09+64%+11%Ex. 99.1, income statement
Net income$126M+118%-14%Ex. 99.1, income statement
Adj. EBITDA$469M+8%+5%Ex. 99.1, income statement
Adj. EBITDA margin25.1%+1.1 pp+0.5 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Healthcare & Water Technologies$1.87B+4%100%Organic sales +4%
Diversified Industrials$1.87B+4%100%Organic sales +5%

Margins and costs

  • Gross margin 35.3% (prior 35.1%, change +0.2 pp)
  • Operating expenses $362M (+4% YoY)
  • One-offs in the quarter Acquisition, integration and separation costs: $15M pretax; Restructuring and asset related charges: $6M pretax; Legal costs (Corian Quartz): $7M pretax; Legal costs (IP matter): $9M pretax; Tax charges (R&D expensing): $43M pretax
  • Effective tax rate 38.7% (prior-year 12.1%, year-to-date 29.5%)
  • Non-GAAP bridge Adds back significant items, amortization, non-op pension/OPEB, Future Reimbursable Indirect Costs, and Corporate DDOB Remediation Costs

KPIs

MetricActualPrior quarterPrior yearChange
Organic sales growth5%4%N/A+1 pp
Transaction-adjusted free cash flow$341M$326M$107M+$15M
Transaction-adjusted free cash flow conversion121%127%60%-6 pp

Guidance

MetricGuidePrior guideChange
Organic sales growthAbout 4.5%Slightly above 4%+0.5 pp
Operating EBITDAAbout $1.785BApproximately $1.76B+$25M
Adjusted EPS$7.47 - $7.52$7.24+$0.23 - $0.28

What drove it

  • Revenue story Net sales increased 4% on 5% organic growth, with both segments growing mid-single digits organically.
  • EPS story Adjusted EPS increased on higher segment earnings, lower net interest expense, lower tax rate, and lower share count.
  • One-off check Separation-related transaction costs and other payments: $2M (includes $2M capex for physical separation)

The good

  • Adjusted EPS of $2.09 (+64% YoY)
  • Transaction-adjusted free cash flow of $341M (+218% YoY)
  • Operating EBITDA margin of 25.1% (+1.1 pp YoY)

The bad

  • GAAP EPS of $1.24 was down 9% QoQ due to higher tax charges and legal costs
  • Transaction-adjusted free cash flow conversion of 121% was down 6 pp QoQ

The ugly

  • none

Open questions

  • The release does not state the prior quarter's organic sales growth for Q2 2026.
  • The release does not state the prior quarter's adjusted EPS.
Full release

DuPont de Nemours (DD) earnings release, November 3, 2026

DuPont de Nemours, Inc. (DD) · Form 8-K, Item 2.02 · Filed · SEC filing

DuPont Reports Third Quarter 2026 Results

Exceeds Third Quarter 2026 Guidance

Raises Full Year 2026 Guidance

Third Quarter 2026 Highlights

• Net Sales of $1.9 billion increased 4%; organic sales increased 5% versus year-ago period

• GAAP Income from continuing operations of $171 million; operating EBITDA of $469 million

• GAAP EPS from continuing operations of $1.24; adjusted EPS of $2.09

• Cash provided by operating activities from continuing operations of $410 million; transaction-adjusted free cash flow of $341 million representing 121% conversion

• Completed $250 million accelerated share purchase and substantially completed $100 million of open market share repurchases in the third quarter

• Announces intent to repurchase $250 million of shares in the fourth quarter

WILMINGTON, Del., Nov. 3, 2026

- DuPont (NYSE: DD) announced its financial results

Financial statements

Income Statement

Three Months Ended September 30, — Consolidated Statements of Operations (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net sales1,8681,7955,3685,156
Cost of sales1,2011,1793,4603,391
Research and development expenses4252131155
Selling, general and administrative expenses260261784757
Amortization of intangibles6871204220
Restructuring and asset related charges - net6184957
Acquisition, integration and separation costs156222167
Equity in earnings (loss) of nonconsolidated affiliates513-6
Sundry income (expense) - net3824116115
Interest expense4085121252
Income from continuing operations before income taxes27991726266
Provision for (benefit from) income taxes on continuing operations108-1121460
Income from continuing operations, net of tax171102512206
Loss from discontinued operations, net of tax-45-209-75-824
Net income (loss)126-107437-618
Net income attributable to noncontrolling interests3161035
Net income (loss) available for DuPont common stockholders123-123427-653
Per common share data:
Earnings per common share from continuing operations - basic1.250.73.71.43
Loss per common share from discontinued operations - basic-0.34-1.58-0.55-6.11
Earnings (loss) per common share - basic0.92-0.883.15-4.68
Earnings per common share from continuing operations - diluted1.240.73.681.43
Loss per common share from discontinued operations - diluted-0.33-1.58-0.55-6.1
Earnings (loss) per common share - diluted0.91-0.883.13-4.67
Weighted-average common shares outstanding - basic134.3139.7135.6139.6
Weighted-average common shares outstanding - diluted135.1140136.4139.9

Income Statement

Reconciliation of "Income from continuing operations, net of tax" to "Operating — Selected Financial Information and Non-GAAP Measures (in millions)

Three Months EndedThree Months EndedNine Months EndedNine Months Ended
Income from continuing operations, net of tax (GAAP)171102512206
+ Provision for income taxes on continuing operations108-1121460
Income from continuing operations before income taxes27991726266
+ Depreciation and amortization155162464488
'- Interest income 1, 227176152
'+ Interest expense 34084121250
'- Non-operating pension/OPEB benefit (costs) credits 1-2-32
'- Foreign exchange gains (losses), net 16-1220-29
+ Future Reimbursable Indirect Costs25875
+ Corporate DDOB Remediation Costs43148
Significant items charge-22-76-76-157
Operating EBITDA (non-GAAP)4694361,3311,219

Income Statement

Significant Items Impacting Results for the Three Months Ended September 30, 202 — Selected Financial Information and Non-GAAP Measures (in millions)

Significant Items Impacting Results for the Three Months Ended September 30, 2026 – Pretax 1Significant Items Impacting Results for the Three Months Ended September 30, 2026 – Net Income 2Significant Items Impacting Results for the Three Months Ended September 30, 2026 – EPS 3
Reported earnings (GAAP)2791681.24
Less: Significant items
Acquisition, integration & separation costs-15-12-0.09
Restructuring and asset related charges - net-6-4-0.03
Other benefits (credits), net 4-1-0.01
Income tax items 5-43-0.31
Total significant items-22-59-0.44
Less: Amortization of intangibles-68-52-0.38
Less: Non-op pension / OPEB benefit costs-2-1-0.01
Less: Corporate DDOB remediation costs-4-2-0.02
Adjusted earnings (non-GAAP)3752822.09

Income Statement

Significant Items Impacting Results for the Three Months Ended September 30, 202 — Selected Financial Information and Non-GAAP Measures (in millions)

Significant Items Impacting Results for the Three Months Ended September 30, 2025 – Pretax 1Significant Items Impacting Results for the Three Months Ended September 30, 2025 – Net Income 2Significant Items Impacting Results for the Three Months Ended September 30, 2025 – EPS 3
Reported earnings (GAAP)91980.7
Less: Significant items
Acquisition, integration and separation costs-62-42-0.3
Restructuring and asset related charges - net-18-14-0.1
Interest rate swap mark-to-market loss 6-4-2-0.02
Qnity financing 7970.05
Other benefits (credits), net 8-1-2-0.01
Income tax items 9480.34
Total significant items-76-5-0.04
Less: Amortization of intangibles-71-55-0.39
Less: Future reimbursable indirect costs-25-19-0.14
Less: Corporate DDOB remediation costs-3-3-0.02
Adjusted earnings (non-GAAP)2661801.29

Income Statement

Significant Items Impacting Results for the Nine Months Ended September 30, 2025 — Selected Financial Information and Non-GAAP Measures (in millions)

Significant Items Impacting Results for the Nine Months Ended September 30, 2025 – Pretax 1Significant Items Impacting Results for the Nine Months Ended September 30, 2025 – Net Income 2Significant Items Impacting Results for the Nine Months Ended September 30, 2025 – EPS 3
Reported earnings (GAAP)2662001.43
Less: Significant items
Acquisition, integration and separation costs-167-131-0.93
Restructuring and asset related charges - net-57-46-0.33
Interest rate swap mark-to-market gain 646370.26
Qnity financing 7970.05
Other benefits (credits), net 81290.07
Income tax items 9460.32
Total significant items-157-78-0.56
Less: Amortization of intangibles-220-172-1.23
Less: Non-op pension / OPEB benefit credits220.01
Less: Future reimbursable indirect costs-75-58-0.41
Less: Corporate DDOB remediation costs-8-5-0.03
Adjusted earnings (non-GAAP)7245113.65

Balance Sheet

September 30, 2026 — Condensed Consolidated Balance Sheets (in millions)

September 30, 2026December 31, 2025
Cash and cash equivalents1,652715
Restricted cash and cash equivalents742
Accounts and notes receivable - net1,7281,669
Inventories1,2381,172
Prepaid and other current assets119121
Assets of discontinued operations1,856
Total current assets4,7445,575
Property, plant and equipment - net of accumulated depreciation (September 30, 2026 - $3,739; December 31, 2025 - $3,565)3,3633,464
Other Assets
Goodwill7,8437,915
Other intangible assets2,7202,936
Investments and noncurrent receivables999432
Deferred income tax assets175282
Deferred charges and other assets965971
Total other assets12,70212,536
Total Assets20,80921,575
Current Liabilities
Short-term borrowings60
Accounts payable1,011995
Income taxes payable5054
Accrued and other current liabilities953882
Liabilities of discontinued operations314
Total current liabilities2,0142,305
Long-Term Debt3,0943,134
Other Noncurrent Liabilities
Deferred income tax liabilities289405
Pension and other post-employment benefits - noncurrent394432
Other noncurrent obligations1,3281,196
Total other noncurrent liabilities2,0112,033
Total Liabilities7,1197,472
Stockholders' Equity
Common stock (authorized 555,555,556 shares of $0.01 par value each; issued 2026: 132,610,823 shares; 2025: 136,398,482 shares)11
Additional paid-in capital38,71838,721
Accumulated deficit-24,544-24,278
Accumulated other comprehensive loss-602-525
Total DuPont stockholders' equity13,57313,919
Noncontrolling interests117184
Total equity13,69014,103
Total Liabilities and Equity20,80921,575

Cash Flow

Nine Months Ended September 30, — Consolidated Statement of Cash Flows (in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)437-618
Loss from discontinued operations-75-824
Net income from continuing operations512206
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization464488
Provision (credit) for deferred income tax and other tax-related items60-54
(Earnings) loss of nonconsolidated affiliates (in excess of) less than dividends received-127
Net periodic pension benefit costs114
Periodic benefit plan contributions-38-34

Cash Flow

Reconciliation of "Cash provided by operating activities - continuing operations — The three and nine months ended September 30, 2025 excludes interest rate swap basis amortization. Refer to details of significant items on page 14. (in millions)

Three Months Ended – Sep 30, 2026Three Months Ended – Sep 30, 2025Nine Months Ended – Sep 30, 2026Nine Months Ended – Sep 30, 2025
Cash provided by operating activities (GAAP) 2 - continuing operations4103221,042473
Capital expenditures-71-74-249-246
Adjusted free cash flow (non-GAAP)339248793227
Separation-related transaction cost and other payments329821234
Transaction-adjusted free cash flow (non-GAAP)341346814461
Adjusted earnings (non-GAAP) 4282180765511
Adjusted free cash flow conversion (non-GAAP)12013810444
Transaction-adjusted free cash flow conversion (non-GAAP)12119210690

(1) for the third quarter ended September 30, 2026 and again raised financial guidance for the full year 2026.

“We delivered another quarter of consistent, high-quality performance, once again exceeding our financial guidance,” said Lori Koch, DuPont Chief Executive Officer. “Mid-single-digit organic growth, strong operating leverage and disciplined capital allocation drove significant adjusted EPS growth. Additionally, we delivered strong free cash flow performance, with 121% conversion, underscoring the quality of our earnings and effective execution.

“We are executing from a position of strength and remain focused on unlocking the full potential of our portfolio to deliver sustained long-term value creation,” Koch concluded.

Third Quarter 2026 Consolidated Results

(1)

(1)

Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.

(2)

Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.

Net sales

• Net sales were up 4% on a 5% increase in organic sales partially offset by a 1% headwind from currency.

• 4% organic sales growth in Healthcare & Water Technologies; 5% organic sales growth in Diversified Industrials.

GAAP Income from continuing operations

• GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.

Operating EBITDA

• Operating EBITDA increased on organic growth and productivity.

Adjusted EPS

• Adjusted EPS increased on higher segment earnings and lower net interest expense, tax rate, and share count.

Cash provided by operating activities from continuing operations

• Cash provided by operating activities from continuing operations in the quarter of $410 million, capital expenditures of $71 million, and separation-related transaction costs and other payments of $2 million resulted in transaction-adjusted free cash flow and related conversion of $341 million and 121%, respectively.

Third Quarter 2026 Segment Highlights

Healthcare & Water Technologies

Net sales

• Net sales increased 4% on organic sales growth in the quarter. Third quarter 2025 net sales included a benefit of $15 million, or 2%, from the order timing shift from the fourth quarter 2025 due to separation-related activities, primarily in Water Technologies.

◦ Healthcare Technologies sales up mid-single digits on an organic basis led by growth in personal protection and medical packaging.

◦ Water Technologies sales up low-single digits on an organic basis on strength in industrial water, semiconductor and specialty markets, partially offset by continued disruptions in the Middle East.

Operating EBITDA

• Operating EBITDA and margin increased on organic growth and productivity.²

Diversified Industrials

Net sales

• Net sales increased 4% as organic sales growth of 5% was partially offset by a currency headwind of 1%. Third quarter 2025 net sales included a benefit of $15 million, or 2%, from the order timing shift from the fourth quarter 2025 due to separation-related activities, primarily in Industrial Technologies.

◦ Building Technologies sales up mid-single digits on an organic basis due to growth in North America and Asia.

◦ Industrial Technologies sales up mid-single digits on an organic basis on continued strength in aerospace and electric vehicle battery applications.

Operating EBITDA

• Operating EBITDA and margin increased on organic growth and productivity.

2026 Financial Outlook

“Our results once again exceeded our financial expectations, demonstrating the strength of our operating model and consistent execution across the businesses. We are again raising our full-year financial outlook and now expect organic growth to be about 4.5%, operating EBITDA to be about $1.785 billion and adjusted EPS to be in the range of $7.47 - $7.52 per share, all at or above the high end of our previously communicated guidance,” said Antonella Franzen, DuPont Chief Financial Officer.

“With continued strength across healthcare, aerospace and industrial water end-markets, we remain well positioned to deliver attractive growth, strong cash generation and effective capital deployment,” Franzen concluded.³

Conference Call

The Company will host a live webcast of its quarterly earnings conference call with investors to discuss its results and business outlook beginning today at 8:00 a.m. ET. The slide presentation that accompanies the conference call will be posted on the DuPont’s Investor Relations Events and Presentations page. A replay of the webcast also will be available on the DuPont’s Investor Relations Events and Presentations page following the live event.... (DuPont

DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and industrial. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPont

TM and all products, unless otherwise noted, denoted with

TM,

SM or ® are trademarks, service marks or registered trademarks of affiliates of DuPont de Nemours, Inc.⁴

Overview

On May 26, 2026, DuPont’s Board of Directors announced a reverse stock split of the Company’s common stock, par value $0.01 per share, at a ratio of 1-for-3, as well as a reduction in the number of authorized shares of its common stock by a corresponding ratio (the "Reverse Stock Split"), as approved by shareholders. The Reverse Stock Split became effective on June 24, 2026. All share and share-related information presented in these interim Consolidated Financial Statements has been retroactively adjusted in all periods presented to reflect the decreased number of shares resulting from the Reverse Stock Split and related impacts.

On April 1, 2026, DuPont completed the sale of the Aramids business (the "Aramids Business" and the divestiture of the Aramids Business, the "Aramids Divestiture") to a subsidiary of ARC Falcon Holdings LP ("Arclin"), a portfolio company of an affiliate of TJC LP for pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of $300 million (the "Aramids Note Receivable") and a non-controlling common equity interest (the "Aramids Equity Consideration"), valued at $325 million, in Arclin which now owns the Arclin global materials business and the Aramids Business. The financial results of the divested Aramids Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations, along with comparative periods.

On November 1, 2025, DuPont completed the separation of its semiconductor and interconnect solutions businesses (the "Electronics Business" and the separation of the Electronics Business, the "Electronics Separation") into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Qnity Distribution"). As a result, the financial results of the divested Electronics Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations for all periods.

Cautionary Statement Regarding Forward-looking Statements

Certain statements in this document may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements often contain words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “seek”, “see”, “will”, “would”, “target”, “outlook”, “stabilization”, “confident”, “preliminary”, “initial”, “continue”, “may”, “could”, “project”, “estimate”, “forecast” and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and the Qnity Distribution, including achievement of the intended tax treatment and the contractual allocation to, and assumption by, Qnity of liabilities and obligations, including certain legacy liabilities, as well as the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Qnity Distribution; (ii) the impact of the Aramids Divestiture on DuPont’s balance sheet, financial condition and future results of operations, as well as any post-closing adjustments, and disputes or unanticipated costs in connection with the Aramids Divestiture; (iii) risks and costs associated with per- and polyfluoroalkyl substances ("PFAS") and the related arrangement among DuPont, Corteva, Inc. and The Chemours Company to share certain eligible costs, including the outcome of pending or future litigation, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing or future remediation and other environmental obligations; the collectability or availability of indemnification, reimbursement or cost-sharing rights; and applicable changes in laws, regulations, or enforcement policies; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with completed and future, if any, divestitures, mergers, acquisitions and other portfolio-management, productivity and infrastructure actions; (v) risks and uncertainties outside the Company’s control that adversely affect the economic and operating environment in which DuPont, its customers and/or its suppliers operate, including inflationary or deflationary pressures, changes in interest rates, foreign currency exchange rates, credit availability, consumer and industrial demand, economic slowdowns or recessions, political and regulatory developments, international trade policies, geopolitical tensions and military conflicts, capital market volatility as well as pandemics, natural disasters, severe weather events and other disruptions; (vi) the availability and cost of raw materials, energy, transportation and logistics, including the Company’s ability to mitigate or offset cost increases, shortages, delays or other supply-chain disruptions through pricing, productivity initiatives, alternative sourcing or otherwise; (vii) risks and uncertainties associated with continuing or expanding geopolitical conflicts, trade disputes, sanctions, trade restrictions and responsive or retaliatory actions, including the imposition, modification, invalidation, reinstatement or replacement of tariffs, export controls, including on exports to China of U.S.-regulated products and technology, or other trade measures; (viii) other risks to DuPont’s business and operations, including cybersecurity, operational and impairment risks; (ix) risks and uncertainties associated with the timing, amount and completion of repurchases under the Company’s share repurchase authorization, including market conditions, the trading price of the Company’s common stock, alternative uses of capital, applicable legal requirements, associated costs and the possibility that repurchases may be reduced, suspended or discontinued prior to completion; (x) the effects of the Reverse Stock Split on the trading price, liquidity and marketability of the Company’s common stock and the Company’s ability to realize the intended benefits of the Reverse Stock Split; and (xi) other risk factors discussed in DuPont’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.⁵

Non-GAAP Financial Measures

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont’s management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 12. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Key Terms

Significant Items

Significant items are items that arise outside the ordinary course of business for the Company and includes items for nonconsolidated affiliates, that the Company’s management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item’s size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. There were no significant items associated with nonconsolidated affiliates recorded for the three and nine month periods ended September 30, 2026 and September 30, 2025.

Future Reimbursable Indirect Costs... (truncated)the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) Qnity not beyond year end 2027 for services and 2040 for site leases and, b) the Aramids Business post the Aramids Divestiture, but not beyond 2028 (such indirect costs “Future Reimbursable Indirect Costs”). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

Corporate DDOB Remediation Costs

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines (“Corporate DDOB Remediation Costs”). DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company.⁶

Non-GAAP Measure Definitions

Organic Sales

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Earnings

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits (“OPEB”) credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about $270 million on a pre-tax basis, or approximately $1.53 per share.

Operating EBITDA, EBITDA Margin & Incremental Margin

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company’s primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company’s cash flow and financial performance, and it is an integral measure used in the Company’s financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and nine month periods ended September 30, 2026.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments... (truncated)non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.⁷

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within

Separation-related transaction costs and other payments. This adjustment is intended to provide insight into the Company's underlying business performance. For the nine months ended September 30, 2026, the Company adjusted $8 million associated with Future Reimbursable Indirect Costs within

Separation-related transaction costs and other payments.

Additionally, $2 and $7 million were reflected in

Separation-related transaction costs and other payments for the three and nine month periods ended September 30, 2026, respectively, for capital expenditures incurred to complete the physical separation of shared locations.

Finally, $6 million of restructuring and short-term incentive program payments to former senior leadership were reflected in

Separation-related transaction costs and other payments for the nine month period ended September 30, 2026. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.⁸

DuPont de Nemours, Inc.

Consolidated Statements of Operations⁹

DuPont de Nemours, Inc.

Condensed Consolidated Balance Sheets¹⁰

DuPont de Nemours, Inc.

Consolidated Statement of Cash Flows¹¹

DuPont de Nemours, Inc.

Select Segment Information and Non-GAAP Measures

1.

Corporate includes expenses of the Corporate function not allocated to specific business in the Company.¹²

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

1.

Included in "Sundry income (expense) - net".

2.

The nine months ended September 30, 2026 and 2025 excludes accrued interest income earned on employee retention credits. The three and nine months ended September 30, 2025 excludes interest earned on cash held in escrow associated with the Qnity financing. Refer to details of significant items on page 14.

3.

The three and nine months ended September 30, 2025 excludes interest rate swap basis amortization. Refer to details of significant items on page 14.

1.

Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow are calculated on a continuing operations basis for all periods presented. Refer to the definitions of Non-GAAP metrics on pages 7-8 for additional information.

2.

Refer to the Consolidated Statement of Cash Flows included in the schedules above for major GAAP cash flow categories as well as further detail relating to the changes in "Cash provided by operating activities - continuing operations" for the nine month periods noted.

3.

Other payments for the three months ended September 30, 2026 includes $2 million related of separation-related capital expenditures. Other payments for the nine months ended September 30, 2026 includes $7 million of separation-related capital expenditures, $6 million related to restructuring and short-term incentive program payments associated with former senior leadership, and $8 million for Future Reimbursable Indirect Costs (as defined in our Non-GAAP definitions).

4.

Refer to page 14 for the Non-GAAP reconciliations of Net income from continuing operations available for DuPont common stockholders to Adjusted Earnings (Non-GAAP).¹³

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

1.

Income (loss) from continuing operations before income taxes.

2.

Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3.

Earnings (loss) per common share from continuing operations - diluted.

4.

Includes legal costs related to personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($7 million pre-tax cost), partially offset by benefits related to an adjustment of the Donatelle contingent earn-out liability ($6 million pre-tax benefit).

5.

Primarily reflects tax charges related to research and development expensing election and non-tax deductible items recorded in the third quarter of 2026.

6.

The three months ended September 30, 2025 includes a non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps. The three months ended September 30, 2025 also includes basis amortization on the 2022 Swaps ($1 million pre-tax cost).

7.

Reflects interest income earned on cash held in escrow.

8.... (truncated)sociated with a pending intellectual property matter ($9 million pre-tax cost), partially offset by benefits related to an adjustment of the Donatelle contingent earn-out liability ($7 million pre-tax benefit).

9.

Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.¹⁴

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

1.

Income (loss) from continuing operations before income taxes.

2.

Net income (loss) from continuing operations available for DuPont common stockholders. The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

3.

Earnings (loss) per common share from continuing operations - diluted.

4.

Reflects legal costs associated with personal injury cases associated with Corian® Quartz, a product within the Diversified Industrials segment ($18 million pre-tax cost) and legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($10 million pre-tax cost), partially offset by benefits related to an adjustment of the Donatelle contingent earn-out liability ($20 million pre-tax benefit) and the accrued interest earned on employee retention credits ($3 million pre-tax benefit).

5.

Primarily reflects tax charges related to research and development expensing election and non-tax deductible items recorded in the third quarter of 2026, offset by a discrete tax benefit relating to a change in tax classification of a non-U.S. legal entity in the first quarter of 2026.

6.

The nine months ended September 30, 2025 includes non-cash mark-to-market gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps. The nine months ended September 30, 2025 also includes basis amortization on the 2022 Swaps ($2 million pre-tax cost).

7.

Reflects interest income earned on cash held in escrow.

8.

Primarily reflects benefits related to an adjustment of the Donatelle contingent earn-out liability ($19 million pre-tax benefit) and the accrued interest earned on employee retention credits ($6 million pre-tax benefit), partially offset by legal costs within the Healthcare & Water Technologies segment associated with a pending intellectual property matter ($14 million pre-tax cost).

9.

Reflects the income tax impact of certain internal restructurings related to the Electronics Separation.¹⁵

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.